ES2870508T3 - Combinación que comprende un compuesto de aminotioléster o una sal farmacéuticamente aceptable del mismo y un compuesto capaz de aumentar el nivel de H2O2 en células cancerosas de un sujeto - Google Patents
Combinación que comprende un compuesto de aminotioléster o una sal farmacéuticamente aceptable del mismo y un compuesto capaz de aumentar el nivel de H2O2 en células cancerosas de un sujeto Download PDFInfo
- Publication number
- ES2870508T3 ES2870508T3 ES16784442T ES16784442T ES2870508T3 ES 2870508 T3 ES2870508 T3 ES 2870508T3 ES 16784442 T ES16784442 T ES 16784442T ES 16784442 T ES16784442 T ES 16784442T ES 2870508 T3 ES2870508 T3 ES 2870508T3
- Authority
- ES
- Spain
- Prior art keywords
- level
- subject
- cancer
- cells
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/131—Amines acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15306650 | 2015-10-15 | ||
| PCT/EP2016/074682 WO2017064241A1 (en) | 2015-10-15 | 2016-10-14 | Combination comprising an aminothiolester compound or a pharmaceutically acceptable salt thereof and a compound able to increase the h2o2 level in cancer cells of a subject |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2870508T3 true ES2870508T3 (es) | 2021-10-27 |
Family
ID=54360386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16784442T Active ES2870508T3 (es) | 2015-10-15 | 2016-10-14 | Combinación que comprende un compuesto de aminotioléster o una sal farmacéuticamente aceptable del mismo y un compuesto capaz de aumentar el nivel de H2O2 en células cancerosas de un sujeto |
Country Status (21)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102941434B1 (ko) * | 2019-07-31 | 2026-03-19 | 어드방스드 비오디자인 | 아미노티올에스터 화합물 및 이의 용도 |
| FR3119314B1 (fr) * | 2021-01-29 | 2025-01-10 | Advanced Biodesign | Nanocapsule lipidique comprenant au moins un composé aminothiolester ou un de ses dérivés pharmaceutiquement acceptable |
| EP4035666A1 (en) * | 2021-01-29 | 2022-08-03 | Advanced Biodesign | Aminothiolester compound or derivative thereof for use as an immunomodulatory agent |
| WO2025229179A1 (en) * | 2024-05-03 | 2025-11-06 | Advanced Biodesign | Use of aminothiolester compounds in combination with hypomethylating agents (hma) for the prevention and treatment of cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2777001B1 (fr) * | 1998-04-01 | 2000-06-09 | Cird Galderma | Derives de l'acide 6,8-dimercaptooctanoique substitues en 6-s et/ou en 8-s par le radical (3-methylthiopropanoyl) et compositions pharmaceutiques destinees au traitement des tumeurs cancereuses |
| FR2809727B1 (fr) * | 2000-05-31 | 2002-07-26 | Galderma Res & Dev | Nouveaux composes aminothiolesters, compositions pharmaceutiques et cosmetiques les contenant et utilisations |
-
2016
- 2016-10-14 PL PL16784442T patent/PL3362094T3/pl unknown
- 2016-10-14 PT PT167844422T patent/PT3362094T/pt unknown
- 2016-10-14 RS RS20210309A patent/RS61572B1/sr unknown
- 2016-10-14 CA CA3001201A patent/CA3001201C/en active Active
- 2016-10-14 CN CN201680066560.4A patent/CN108348612A/zh active Pending
- 2016-10-14 MX MX2018004381A patent/MX377725B/es active IP Right Grant
- 2016-10-14 WO PCT/EP2016/074682 patent/WO2017064241A1/en not_active Ceased
- 2016-10-14 HR HRP20210358TT patent/HRP20210358T1/hr unknown
- 2016-10-14 AR ARP160103143A patent/AR106351A1/es unknown
- 2016-10-14 JP JP2018538936A patent/JP7062592B2/ja active Active
- 2016-10-14 ES ES16784442T patent/ES2870508T3/es active Active
- 2016-10-14 EP EP16784442.2A patent/EP3362094B1/en active Active
- 2016-10-14 DK DK16784442.2T patent/DK3362094T3/da active
- 2016-10-14 SM SM20210270T patent/SMT202100270T1/it unknown
- 2016-10-14 US US15/768,468 patent/US10406125B2/en active Active
- 2016-10-14 LT LTEP16784442.2T patent/LT3362094T/lt unknown
- 2016-10-14 HU HUE16784442A patent/HUE054247T2/hu unknown
- 2016-10-14 SI SI201631109T patent/SI3362094T1/sl unknown
-
2018
- 2018-04-12 IL IL258658A patent/IL258658B/en active IP Right Grant
- 2018-04-12 ZA ZA2018/02400A patent/ZA201802400B/en unknown
-
2021
- 2021-03-02 CY CY20211100174T patent/CY1123916T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RS61572B1 (sr) | 2021-04-29 |
| IL258658A (en) | 2018-06-28 |
| US10406125B2 (en) | 2019-09-10 |
| WO2017064241A1 (en) | 2017-04-20 |
| MX377725B (es) | 2025-03-11 |
| HK1251477A1 (en) | 2019-02-01 |
| JP2018531995A (ja) | 2018-11-01 |
| DK3362094T3 (da) | 2021-03-01 |
| HRP20210358T1 (hr) | 2021-04-16 |
| HUE054247T2 (hu) | 2021-08-30 |
| SI3362094T1 (sl) | 2021-04-30 |
| LT3362094T (lt) | 2021-05-10 |
| CN108348612A (zh) | 2018-07-31 |
| JP7062592B2 (ja) | 2022-05-06 |
| EP3362094A1 (en) | 2018-08-22 |
| IL258658B (en) | 2021-04-29 |
| CY1123916T1 (el) | 2022-05-27 |
| CA3001201C (en) | 2023-07-11 |
| PT3362094T (pt) | 2021-04-15 |
| AR106351A1 (es) | 2018-01-03 |
| PL3362094T3 (pl) | 2021-10-11 |
| SMT202100270T1 (it) | 2021-07-12 |
| MX2018004381A (es) | 2018-05-11 |
| US20180303773A1 (en) | 2018-10-25 |
| BR112018007480A2 (en) | 2018-10-23 |
| CA3001201A1 (en) | 2017-04-20 |
| EP3362094B1 (en) | 2021-02-17 |
| ZA201802400B (en) | 2020-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sun et al. | Activation of the p62‐Keap1‐NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells | |
| ES2863996T3 (es) | Terapia de combinación para el tratamiento del cáncer | |
| US10793514B2 (en) | Glutamine transport inhibitors and methods for treating cancer | |
| ES2424022T3 (es) | Composiciones y usos para tratar la esclerosis múltiple | |
| JP7062592B2 (ja) | アミノチオールエステル化合物またはその薬学的に許容される塩および対象の癌細胞におけるｈ２ｏ２濃度を増大し得る化合物の組み合わせ | |
| US20210214390A1 (en) | Rapaglutins, novel inhibitors of glut and use thereof | |
| ES2867965T3 (es) | Compuestos de aminotioléster o sales farmacéuticamente aceptables de los mismos, para utilizar en el tratamiento del cáncer | |
| ES2535452B1 (es) | Potenciación del efecto del metotrexato mediante el uso combinado con estatinas lipofílicas | |
| US20230130791A1 (en) | A Combined Inhibition of EGFR and NRF2 in The Treatment of Malignant Glioma | |
| Zhang et al. | Inhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644: an aminobisphosphonate derivative | |
| BR112018007480B1 (pt) | Composição farmacêutica, uso de uma combinação e método para a seleção de um indivíduo | |
| BR112018007310B1 (pt) | Método in vitro para selecionar um indivíduo que sofre de um câncer | |
| HK1251477B (en) | Combination comprising an aminothiolester compound or a pharmaceutically acceptable salt thereof and a compound able to increase the h2o2 level in cancer cells of a subject | |
| WO2023014296A2 (en) | Molecular glue and sall4 degrader | |
| HK1251476B (en) | Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer | |
| ES2897790T3 (es) | Un agente que aumenta la expresión del agonista asociado a Bcl2 de la muerte celular para el tratamiento del cáncer | |
| Li | Targeting Heat Shock 27 Kda Protein Induces Androgen Receptor Degradation | |
| US20220082564A1 (en) | Marker for assessing sensitivity to combination anticancer drug |